Johnson & Johnson Beats Estimates Yet Again

Johnson & Johnson (NYS: JNJ) reported earnings on Jan. 24. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Johnson & Johnson met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved and earnings per share dropped significantly.

Margins dropped across the board.

Revenue details
Johnson & Johnson tallied revenue of $16.3 billion. The 18 analysts polled by S&P Capital IQ predicted sales of $16.3 billion. Sales were 3.9% higher than the prior-year quarter's $15.6 billion.


Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
Non-GAAP EPS came in at $1.13. The 22 earnings estimates compiled by S&P Capital IQ anticipated $1.09 per share on the same basis. GAAP EPS of $0.08 for Q4 were 89% lower than the prior-year quarter's $0.70 per share.


Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 67.2%, 60 basis points worse than the prior-year quarter. Operating margin was 20.3%, 170 basis points worse than the prior-year quarter. Net margin was 1.3%, 1,110 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $16.5 billion. On the bottom line, the average EPS estimate is $1.32.

Next year's average estimate for revenue is $68.5 billion. The average EPS estimate is $5.21.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 13,482 members out of 13,964 rating the stock outperform, and 482 members rating it underperform. Among 3,306 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 3,246 give Johnson & Johnson a green thumbs-up, and 60 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Johnson & Johnson is outperform, with an average price target of $71.53.

The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Johnson & Johnson the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.

At the time this article was published Seth Jayson owned shares of the following at the time of publication: Johnson & Johnson. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story